# Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

> **NCT02128269** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Antiphospholipid (aPL)-Positive

## Interventions

- **BIOLOGICAL:** Study Drug- ALXN1007

## Key facts

- **NCT ID:** NCT02128269
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Screening discontinued early due to slow patient enrollment
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128269, "Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02128269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*